Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, announces a $1 million investment by the Investment Accelerator Fund-Life Sciences (IAF-LS).
Julie A. Fotheringham - Partner, Hageman Communications
Julie.fotheringham@hageman.ca 416-951-7988
We are located in the MaRS Discovery District
Interface Biologics Inc.
MaRS Centre, South Tower
101 College Street, Suite 300
Toronto, ON, M5G 1L7